1076 related articles for article (PubMed ID: 31899205)
1. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
2. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
3. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
4. Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function.
Jiang X; Peng J; Xie Y; Xu Y; Liu Q; Cheng C; Yan P; Xu S; Wang Y; Zhang L; Li H; Li Y; Li B; Han J; Yu D
Cell Death Differ; 2023 Aug; 30(8):1931-1942. PubMed ID: 37419985
[TBL] [Abstract][Full Text] [Related]
5.
Jiao Y; Li Y; Fu Z; Hou L; Chen Q; Cai Y; Jiang P; He M; Yang Z
Dis Markers; 2019; 2019():9037131. PubMed ID: 31781311
[TBL] [Abstract][Full Text] [Related]
6. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
8. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis.
Liu Y; Meng F; Wang J; Liu M; Yang G; Song R; Zheng T; Liang Y; Zhang S; Yin D; Wang J; Yang H; Pan S; Sun B; Han J; Sun J; Lan Y; Wang Y; Liu X; Zhu M; Cui Y; Zhang B; Wu D; Liang S; Liu Y; Song X; Lu Z; Yang J; Li M; Liu L
Clin Cancer Res; 2019 Sep; 25(17):5407-5421. PubMed ID: 31175094
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
10. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
11. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
12. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
14. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma.
Choi Y; Oh ST; Won MA; Choi KM; Ko MJ; Seo D; Jeon TW; Baik IH; Ye SK; Park KU; Park IC; Jang BC; Seo JY; Lee YH
Biochem Biophys Res Commun; 2016 Sep; 478(4):1674-81. PubMed ID: 27592554
[TBL] [Abstract][Full Text] [Related]
15. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
17. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
[TBL] [Abstract][Full Text] [Related]
18. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
19. OGDHL is a modifier of AKT-dependent signaling and NF-κB function.
Sen T; Sen N; Noordhuis MG; Ravi R; Wu TC; Ha PK; Sidransky D; Hoque MO
PLoS One; 2012; 7(11):e48770. PubMed ID: 23152800
[TBL] [Abstract][Full Text] [Related]
20. Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling.
Ma APY; Yeung CLS; Tey SK; Mao X; Wong SWK; Ng TH; Ko FCF; Kwong EML; Tang AHN; Ng IO; Cai SH; Yun JP; Yam JWP
Cancer Res; 2021 Jul; 81(13):3679-3692. PubMed ID: 33975883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
